Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target

Autor: Janne W Bolt, Caroline J Aalbers, Laura Walet, Leonieke J J van Mens, Christiaan van Denderen, Irene van der Horst-Bruinsma, Lisa G M van Baarsen, Robert Landewé, Marleen G H van de Sande
Rok vydání: 2023
Předmět:
Zdroj: Rheumatology.
ISSN: 1462-0332
1462-0324
DOI: 10.1093/rheumatology/kead155
Popis: Objective ‘Treat-to-target principles’ are advised for axial spondyloarthritis (axSpA), although a clear target is not yet defined and targets do not always reflect inflammation. Treat-to-target use and motives for treatment choices in clinics are unknown. Therefore, we studied the presence of residual disease activity according physician’s opinion, patient’s opinion and composite indices and compared them to the subsequent treatment decisions. Methods This cross-sectional multicentre study included 249 patients with a clinical diagnosis of axSpA ≥6 months. Remission and low disease activity according to the BASDAI ( Results A total of 115/249 (46%) patients were in remission according to the physician and 37% (n = 43) of these patients reached remission according to the BASDAI. In 51/83 (60%) of the patients with residual disease activity according to the physician and a BASDAI >3.5 the treatment was left unchanged, either because of low disease activity as rated by the physician [n = 15 (29%)] or because of a combination of low disease activity with non-inflammatory complaints or comorbidities [n = 11 (25%)]. Retrospective treat-to-target evaluations showed that treatments were most frequently intensified in patients with arthritis or inflammatory back pain and less often in patients with other (non-inflammatory) musculoskeletal comorbidities. Conclusion This study shows that physicians do not always strictly apply treat-to-target in case of residual disease activity in axSpA. Usually, they accept low disease activity as satisfactory.
Databáze: OpenAIRE
Externí odkaz: